Here’s how ASX healthcare shares performed in FY22

ASX healthcare shares were a mixed basket this past financial year.

After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January.

The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around 5% into the red for the 12 months to June 30. It traded in sideways territory from January to June.

These three healthcare shares are worthy of note. Let’s take a look at each one.

CSL Limited (ASX: CSL)

The biotech giant is a natural on this list. It suffered a similar fate to the wider sector on the charts in FY22.

After soaring to a 52-week high price of $318 on 24 November, ASX investors sold CSL down to a 52-week low of $243 per share by February.

CSL announced its acquisition offer for Vifor Pharma in December last year. It issued US$4 billion of bonds in the US debt capital markets to finance the transaction.

The six issued notes pay a coupon ranging from 3.85% to 4.95% per annum and range from five years to 40 years in tenor.

The CSL share price finished FY22 in a bullish uptrend that has continued into the new financial year. It is down 3.5% in 2022 so far and trading at $285.66 at the time of writing.

ResMed CDI (ASX: RMD)

Sleep treatment company ResMed recognised a series of losses in FY22.

ResMed reversed out of a bullish uptrend in late 2021. The ResMed share price fell from a high of $40.28 on 13 September to a 52-week low of $27.63 in May.

Despite its struggles, several analysts rate the ResMed share price a buy. Fundamentally, they say, the company is strong, and its long-term outlook is attractive.

Morgans is bullish on ResMed and says “nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform.”

Meanwhile, analysts at HB Insights are also bullish. They reckon a product recall by ResMed’s competitor is a boon for the company.

“RMD is well positioned to deal with demand supply mechanics and now faces more demand than it can fulfil [with the competitor removed]” the broker said.

“This, along with new product launches as a catalyst, provides the economic pillars for top line expansion over the coming years,” it added.

“We are seeking … a price objective of $245 in the next 6-12 months, and are bullish in the near term amid catalysts described above,” HB Insights concluded.

This ASX healthcare share is trading down 0.92% today at $32.20.

Immutep Ltd (ASX: IMM)

Finally, Immutep is worth a mention in this list. The developer of LAG-3 immunotherapy cancer treatments had a choppy year and landed deep in the red.

Nevertheless, it released several updates across the 12 months regarding its flagship label, known as etfi.

Etfi gained more clinical trial momentum in FY22. It was most recently recognised at the American Society of Clinical Oncology 2022 special edition.

However, ASX investors appear to have overlooked this clinical progress, and have traded the Immutep share price down to a 52-week low of 29 cents on 30 June.

It has now levelled back up to trade at 32 cents.

The post Here’s how ASX healthcare shares performed in FY22 appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why this broker is tipping the ResMed share price to rise 17%
• Beating the benchmark: Why this broker is betting on the CSL share price for outperformance
• Here’s what happened to the CSL share price in June
• How did the Vanguard Australian Shares Index ETF perform in June?
• Pricing power: 2 ASX shares that can fight stagflation

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/oKZxNBU